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Abstract
AIM
To assess circulatory levels of interleukin-18 (IL-18) 
and determine whether the presence of IL-18 promoter 
polymorphism influences metabolic syndrome phenotypes. 
METHODS 
This study recruited one hundred and eighty individuals 
divided into three groups with sixty subjects each as: 
Normal weight (18.0-22.9 kg/m2), overweight (23.0-25.9 
kg/m2) and obese (> 26.0 kg/m2) according to South 
Asian criteria of BMI. Fasting blood glucose (FBG), 
Lipid profile, insulin, IL-18 and tumor necrosis factor 
(TNF)α were measured using ELISA kits, whereas low 
density lipoprotein (LDL)-cholesterol, insulin resistance 
(HOMA-IR) and insulin sensitivity (QUICKI) were 
calculated. The body fat percentage (BF) was measured 
through bioelectrical impedance analysis; waist and 
hip circumference were measured. Genotyping of IL-18 
-607 C/A polymorphism was performed by using tetra-
primer amplification refractory mutation system. Student 
t  test, One-way analysis of variance, Hardy-Weinberg 
equilibrium, Pearson’s χ 2 test and Pearson’s correlation 
were used, where a P  value < 0.05 was considered 
significant.
RESULTS
In an aged matched study, obese subjects showed 
higher levels of FBG, cholesterol, triglycerides and 
LDL levels as compared to normal weight (P  < 0.001). 
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Highest levels of IL-18 and TNF levels were also seen 
in obese subjects (IL-18: 58.87 ± 8.59 ng/L) (TNF: 
4581.93 ± 2132.05 pg/mL). The percentage of IL-18 
-607 A/A polymorphism was higher in overweight and 
obese subjects vs  normal weight subjects (P  < 0.001). 
Moreover, subjects with AA genotype had a higher 
BF, insulin resistance, TNFα and IL-18 levels when 
compared with subjects with AC (heterozygous) or CC 
(wild type) genotypes. However, we did not find any 
difference in the lipid profile between three subgroups. 
CONCLUSION
This preliminary data suggests that IL-18 polymorphism 
affects IL-18 levels that might cause low grade inflam-
mation, further exacerbated by increased TNFα. All 
these increase the susceptibility to develop MetS. 
Further studies are required to validate our findings. 
Key words: Metabolic syndrome; Interleukin-18; Polymor-
phism; Obesity; Body fat; High density lipoprotein; Low 
density lipoprotein; Insulin
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Interleukin-18 (IL-18 ) gene polymorphisms 
may influence the expression of its levels. This in 
turn increases the risk of metabolic syndrome (MetS). 
Therefore, we aimed to assess the circulatory levels 
of IL-18 and determine whether the presence of IL-18 
promoter polymorphism influences MetS phenotypes. 
Subjects with AA genotype had a higher body fat, insulin 
resistance, tumor necrosis factor α and IL-18 levels 
when compared with subjects with AC (heterozygous) or 
CC (wild type) genotypes. This preliminary data suggests 
that IL-18 polymorphism affects IL-18 levels that might 
cause low grade inflammation. All these increase the 
susceptibility to develop MetS. Further studies are 
required to validate our findings.
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INTRODUCTION
Interleukin-18 (IL-18), also known as interferon-gamma 
inducing factor, is a pro-inflammatory cytokine that 
belongs to the IL-1 superfamily. It is not only produced 
by immune cells like macrophages but is also express 
by keratinocytes, osteoblasts cells, pituitary gland and 
adrenal cortical cells[1]. IL-18 serves as a mediator of 
immune response by stimulating T-helper cells (Th-1) 
against infections[2]. In healthy individuals, its production 
by the host is in line to utilization as a defense and 
healing mechanism, maintained in a fine balance. 
However, it has been established that its over-production 
results in autoimmune inflammatory disorders[3]. 
Apart from its role in inflammation, IL-18 has also 
been associated with increased visceral adiposity and 
obesity. Studies report abnormally elevated circulating 
IL-18 levels in obese individuals while reduction in body 
weight is found to results in a concomitant reduction 
in IL-18 levels, supporting the fact that reduction in 
adipose tissue leads to a decline in secretion of pro-
inflammatory cytokines[4]. Furthermore, IL-18 mediated 
inflammation is associated with cardiovascular disorders 
suggesting its role in atherosclerotic diseases[5]. In the 
context of hyperglycemia, there are certain oxidative 
mechanisms that increase circulating cytokines including 
IL-18, thereby linking high blood glucose to the pro-
inflammatory cytokines[6]. Various studies have reported 
elevated serum IL-18 in patients with type 2 diabetes[7].
As the presence of risk factors for cardiovascular 
disease and type 2 diabetes mellitus increases the 
threat of developing metabolic syndrome (MetS), 
IL-18 has been implicated to play a critical role in such 
conditions[8]. In terms of polymorphism in the IL-18 
gene, various SNP are reported in association with 
diseases like type 1 diabetes[9], chronic hepatitis B virus 
infection[10], asthma[11]. 
The IL-18 gene is located on chromosome 11 (11-
q22.2-22.3), and contains many polymorphism, especi-
ally in the promoter region[12]. One such polymorphism 
is the -607 A/C that seems to affect the expression 
level of IL-18 at transcription level[13]. In addition, it has 
been associated with the development of cardiovascular 
disease such as vascular endothelial damage and forma-
tion of atherosclerosis[14]. The relationship between 
the promoter region polymorphism of IL-18 and MetS 
phenotypes is scarce. Therefore, we aimed to assess the 
circulatory levels of IL-18 and determine whether the 




This cross-sectional study recruited 180 healthy 
male individuals from the waiting areas of outpatient 
department of Aga Khan University. The subjects were 
divided into three groups. Group A: normal weight 
(18.0-22.9 kg/m2), Group B: overweight (23.0-25.9 kg/
m2), Group C: obese (> 26.0 kg/m2) according to South 
Asian criteria of BMI[15]. Subjects with diabetes mellitus, 
hypertension [resting blood pressure (BP) 170/100 
mmHg], dyslipidemia, body weight fluctuation of 5 kg in 
the recent 6 mo, smokers, alcoholics, any acute illness 
during last one month, as well as those taking anti-
inflammatory medications were excluded. This study 
was approved by the institutional ethical committee and 
all participants gave a written and informed consent to 
participate in this study. The sample size was calculated 
306 June 15, 2017|Volume 8|Issue 6|WJD|www.wjgnet.com
in order to achieve 80% power to detect an odds ratio 
of at least 2 among obese, with a two sided alpha value 
of 95% (NCSS/PASS version 11 software for power 
analysis and sample size).
Anthropometric data
The weight and height of all the subjects were mea-
sured in kilograms and meters respectively, using a 
weight scale with a built-in Stadiometer (ZT-120 Health 
Scale, Nanjing Everich China). Waist circumference 
and hip circumference was measured using the WHO 
protocol[16]. Subjects were asked to stand in an erect 
posture wearing light clothing. BMI was calculated by 
dividing weight by height squared (kg/m2)[17]. While 
body fat percentage was measured using Diagnostic 
Scale BG55 (Beurer Germany) through bioelectrical 
impedance matching/analysis. 
Biochemical profile
Six milliliter of blood was collected from the study 
participants after an overnight fast of 12 h. Fasting 
plasma glucose and Lipid profile were measured using 
commercially available kits as per the vendor’s instruction 
(Merck, France). Low density lipoprotein (LDL)-cholesterol 
levels were calculated using the Friedewald equation[18]. 
Fasting insulin, IL-18 and TNFα levels were measured 
using an ELISA kit (DIA source Immuno Assay S.A., 
Belgium). Insulin resistance was calculated using the 
homeostasis model assessment of insulin resistance 
(HOMA-IR) index [fasting insulin (units per milliliter) × 
fasting glucose milligram/deciliter)/405][19], and insulin 
sensitivity was calculated by (QUICKI) {1/[log(fasting 
insulin) + log(fasting glucose)]}[20]. 
Genotyping
DNA extraction was performed using commercially 
available Qiagen DNA extraction kit (Cat. #51185, 
Valencia, CA United States). Genotyping of IL-18 -607 
C/A polymorphism was performed by using tetra-primer 
amplification refractory mutation system (TARMS-PCR) 
using the GoTaq® Hot Start Green Master Mix (Cat. 
# M5122, Promega Corporation, United States) as 
per the manufacturer’s instructions with the following 
cycling conditions for PCR: 1 cycle for 5 min at 95 ℃ 
for initial denaturation followed by 35 cycles at 95 ℃ 
for 30 s, 55 ℃ for 30 s, 72 ℃ for 30 s followed by a 
final extension of 10 min at 72 ℃. PCR products were 
electrophoresed in 2% agarose gel. Genotyping quality 
control was performed in 10% of the samples by 
duplicate checking (rate of concordance in duplicates 
was > 99 %). Tetra arms primers used for amplifying 
IL-18 -607 (C/A) were as follows: Control Band (Outer 
forward: CCTACAATGTTACAACACTTAAAAT; Outer 
reverse: ATAAGCCCTAAATATATGTATCCTTA) (product 
size 440 bp); A allele [Inner forward: GATACCA-
TCATTAGAATTTTGTG (product size 278 bp)] and C allele 
[Reverse inner GCAGAAAGTGTAAAAATTATCAA (product 
Size 208 bp)] (Figure 1). The study was approved 
by the institutional ethical review board (3597-BBS-
ERC-15), and all subjects gave a written and informed 
consent. 
Statistical analysis
A descriptive statistical analysis of continuous vari-
ables was performed using SPSS (version 21; SPSS 
Inc., Chicago, IL, United States). Data on continuous 
variables were calculated as mean ± SD, whereas 
data on categorical variables was presented as frequen-
cies and percentages. Statistical comparisons were 
computed using a student t test, one-way analysis 
of variance (ANOVA) and Pearson’s χ2 test of indepen-
dence. Pearson’s correlation (r) were used to determine 
the correlation between serum IL-18 levels and lipid 
profile, fasting blood glucose, insulin and body fat 
parameters. Hardy-Weinberg equilibrium (HWE) was 
calculated for IL-18 SNP. Significance and effect size of 
minor allele with study parameters were determined 
under an additive model of inheritance. In all statistical 
analysis performed P values < 0.05 were considered 
significant.
RESULTS
Table 1 shows the biophysical and biochemical data 
of the study subjects. All three groups were aged 
matched, therefore no significant difference was 
observed amongst the groups. Considerable difference 
was observed in terms of raised BMI and BF in obese 
group as compared to controls (P < 0.001). Similarly, 
obese group had a higher FBG, insulin, cholesterol, 
triglycerides and LDL levels as compared to controls 
(P < 0.001). Interestingly no differences were seen in 
the high density lipoprotein (HDL) levels of our study 
groups. IL-18 and TNF levels showed an increasing 
trend from normal weight to obese, with the highest 
levels seen in obese group (IL-18: 58.87 ± 8.59) (TNF: 
4581.93 ± 2132.05). We next performed the correlation 
of IL-18 levels with the study parameters and report 
a strong positive correlation of IL-18 with BMI, Waist 
circumference, FBG, insulin, HOMA-IR, QUICKI, Choles-
Marker    CC      AA          CC         CC       CC        B
Figure 1  Genotype distribution of selected samples for the tetra arms 
PCR. Marker is 100 bp DNA ladder and B is blank.
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terol, and TNFα while a moderate correlation was 
seen for LDL and BF. All these associations remained 
significant after multiple adjustments for confounding 
factors like age, BMI and BF, except insulin (Table 2 and 
Figure 2). 
The genotype distributions was in accordance 
with HWE in total study subjects (P = 0.222) and in 
subgroups (Normal Weight: P = 0.281; Overweight: P 
= 0.663; Obese: P = 0.196). The percentage of IL-18 
-607 A/A genotype was higher in overweight and obese 
subjects vs normal weight subjects (P < 0.001 Table 
3). Moreover, subjects with AA genotype had a higher 
BF, insulin resistance, TNFα and IL-18 levels when 
compared with subjects with AC or CC genotypes. 
However, we did not find any difference in the lipids 
profile between three subgroups (Table 4). 
DISCUSSION
IL-18 is pleiotropic cytokine acting in both acquired and 
innate immunity. Additionally it also acts to stimulate 
the production of TNFα[1] which is also a key player 
associated with higher BMI[21,22]. These cytokines in turn 
predispose an individual to develop MetS phenotypes. 
In an age matched study group, we observed a 
positive association of serum IL-18 concentration with 
BMI, FBG, and serum TG, where body fat percentage 
contributed most to the variation of serum IL-18 
concentration. Furthermore, our study shows circulating 
IL-18 levels were associated with measures of insulin 
resistance (HOMA-IR) and decreased insulin sensitivity 
(QUICKI) in apparently healthy obese subjects. Among 
other factors causing a rise in IL-18 levels, nutritional 
  Variables Normal weight
(18-22.9 kg/m2)
(n  = 60)
Overweight
(23-25.9 kg/m2)
(n  = 60)
Obese
(>26 kg/m2)
(n  = 60)
P value
  Age (yr)    26.21 ± 3.876   25.76 ± 4.059  27.30 ± 5.389 NS
  BMI (kg/m2) 20.48 ± 1.30  24.20 ± 0.911   28.59 ± 3.341,2 < 0.001
  Body fat (%) 19.26 ± 7.17  28.70 ± 9.101   34.89 ± 4.471,2 < 0.001
  Waist circumference (cm)   88.03 ± 10.53 88.46 ± 7.69 1.9.26 ± 11.47 < 0.001
  Hip circumference (cm)   77.69 ± 11.78 84.43 ± 0.69 100.41 ± 12.89 < 0.001
  WHR (cm)   0.87 ± 0.05   0.871 ± 0.054    0.91 ± 0.073 < 0.001
  Fasting blood glucose (mg/dL)   89.31 ± 15.23  105.59 ± 12.501 119.00 ± 25.711 < 0.001
  Insulin (uIU/mL) 20.48 ± 7.95  34.96 ± 4.471   41.13 ± 7.811,2 < 0.001
  HOMA-IR   4.70 ± 2.66    9.05 ± 1.341   11.88 ± 2.811,2 < 0.001
  QUICKI   0.31 ± 0.02    0.27 ± 0.001   0.27 ± 0.011 < 0.001
  Cholesterol (mg/dL) 145.72 ± 30.08 147.44 ± 37.91   209.06 ± 55.511,2 < 0.001
  Triglyceride (mg/dL) 124.82 ± 43.92 137.58 ± 65.60   167.03 ± 55.991,2 < 0.001
  HDL(mg/dL) 39.96 ± 9.38 38.37 ± 8.00 36.40 ± 6.40 NS
  LDL(mg/dL)   75.43 ± 30.03   79.57 ± 40.01   134.78 ± 58.991,2 < 0.001
  TNFα (pg/mL)     810 ± 1233     4455 ± 23901   4581 ± 21321 < 0.001
  IL-18 (ng/L) 25.34 ± 6.57   41.96 ± 4.501   58.87 ± 8.591,2 < 0.001
Table 1  Biophysical and biochemical data of the study subjects
Values are expressed as mean ± SD. Comparison between groups was tested by One way analysis of variance followed by Tuckey’s post hoc test. 
1Statistically significant as compared to normal weight; 2Statistically significant as compared to overweight. Significance set at P value < 0.05. HOMA-
IR: Homeostasis model of insulin resistance; QUICKI: Quantitative insulin sensitivity check index; HDL: High density lipoprotein; LDL: Low density 
lipoprotein; TNF: Tumor necrosis factor; WHR: Waist to hip ratio.
  Variable Unadjusted r Adjusted r
(age, BMI and 
body fat %)
  Age (yr) 0.302 --
  BMI (kg/m2) 0.751 --
  Body fat (%) 0.518 --
  Waist circumference (cm) 0.333 0.413
  Hip circumference (cm) 0.695   -0.110NS
  Fasting blood glucose (mg/dL) 0.559 0.376
  Insulin (uIU/mL) 0.655    0.205NS
  HOMA-IR 0.699 0.344
  QUICKI            -0.600 -0.496
  Cholesterol (mg/dL) 0.514  0.265
  LDL(mg/dL) 0.464  0.245
  TNFα 0.577  0.491
Table 2  Correlation of interleukin-18 with metabolic syndrome 
phenotypes
Pearson Correlation was applied. All associations remained significant 
after adjustment except insulin (NSnon-significant), statistically significant 
P value < 0.01. HOMA-IR: Homeostasis model of insulin resistance; 
QUICKI: Quantitative insulin sensitivity check index; LDL: Low density 
lipoprotein; TNF: Tumor necrosis factor.
  Genotype distribution 
CC AC AA P value
  Normal weight 27 23 10 < 0.001
  Overweight 11 25 24
  Obese 12 24 24
  Allele frequency
A allele C allele OR (95%CI) P value
  Normal weight 42 (35.0) 78 (65.0) - -
  Overweight 47 (39.17) 73 (60.83) 2.81 (1.66-4.68)1 < 0.001
  Obese 48 (40.00) 72 (60.00) 2.91 (1.72-4.94)2
Table 3  Genotype frequency among study subjects
In all divisions the HWE was > 0.05. 1Normal weight vs overweight and 
2normal weight vs obese calculated by Pearson’s χ 2 test. Allele frequencies 
are given as absolute values with percentage given in parentheses.
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states, such as hyperglycemia, and fat mass increase[23] 
have been validated the most. In particular, adipocytes 
from obese individuals were found to secrete a threefold 
higher IL-18 vs lean ones[24], identifying an essential 
role of IL-18 in regulating fat distribution[25]. Though, 
an animal study demonstrated that deficiency of 
IL-18 resulted in obesity and insulin resistance in mice 
and the phenotype could be rescued by exogenous 
administration of IL-18[26]. 
We further evaluated the presence of a promote 
gene polymorphism in these subjects. Interestingly, 
we report that subjects with AA genotype had a higher 
BMI, BF, insulin resistance and IL-18 levels. Moreover, 
raised IL-18 increased the chances of developing 
of MetS in our study subjects (OR = 2.72, 95%CI: 
1.28-5.74, P = 0.008). Results regarding the association 
of -607 SNP and MetS phenotypes are not consistent. 
One study reported a decreased proportion of A/A 
genotype in type 1 diabetic patients relative to control 
subjects[9]. However, another[27] found higher proportion 
of A/A genotype in type 1 diabetic patients but no risk 
association could be identified. Another study, conducted 
in Chinese population reported a higher proportion of 
A/A genotype in patients with type 2 diabetes, which is 
somewhat similar to our report. Therefore, it is empirical 
to identify the different genetic influences among 
different races when considering genotype data and 
risk association. For instance, A allele at position of -607 
was a protective allele from type 1 diabetes in a Polish 
population[9], while in a population from United Kingdom, 
the significant association was not found[27]. 
These seemingly conflicting results suggested that 
IL-18 probably acts as a feedback signal for obesity, 
hyperglycemia, and positive energy balance. Alter-
natively, it might be a consequence of sensitivity in 
those subjects to the effect of IL-18. This may prove 
that inflammatory marker (IL-18) may just not be an 
indicator for chronic inflammation and obesity but has 
a role in pathway leading to MetS. Another outcome of 
our study was the relation of IL-18 with increased levels 
of cholesterol and LDL. This opens up another avenue 
about the role of IL-18 in atherosclerosis and presents a 
great opportunity to work further in this field. Some of 
previous studies have shown association of circulating 
IL-18 levels with cardiovascular mortality among patients 
with coronary artery disease[5]. However, contrasting data 
also exists which states no or weak association of IL-18 
levels with BMI and lipid profile in European men[28], this 
may suggest that association may vary according to the 
population. In addition to Interleukin 18, recent repost 
suggested that other variants such as Interleukin-23/
IL-17 axis has also been independently affiliated with 
obesity in women especially related to increase visceral 
fat, insulin resistance, and leptin levels[29] as well as 
in causing hypertension and increased cardiovascular 
risk[30].
One of the limitations of this study rests in the 
study-design. As this was a cross sectional study the 
association of IL-18 with all of these metabolic traits 
could not be established, further more we were unable 
to record the nonalcoholic fatty liver disease through 
  Variables CC (n  = 57) AC (n  = 72) AA (n  = 51) P  value
  BMI (kg/m2) 23.36 ± 4.05 24.60 ± 4.137 25.25 ± 3.351      0.05
  Body fat (%) 24.70 ±10.30 28.70 ± 8.592 29.31 ± 9.461    < 0.001
  Waist circumference(cm) 92.78 ± 16.61 96.48 ± 13.21 97.32 ± 13.82        0.085
  Hip circumference (cm) 74.18 ± 4.23 67.40 ±3.99 64.51 ± 4.84        0.694
  WHR (cm) 0.88 ± 0.069 0.88 ± 0.061 0.89 ± 0.06        0.490
  Fasting blood glucose (mg/dL) 103.41 ± 23.43 101.79 ± 21.01 110.32 ± 21.97  > 0.05
  Insulin (uIU/mL) 28.83 ± 11.91 32.76 ± 11.392 34.67 ± 9.611        0.002
  HOMA-IR 7.75 ± 4.34 8.44 ± 3.71 9.47 ± 3.001        0.007
  QUICKI 0.29 ± 0.02 0.28 ± 0.02 0.28 ± 0.011        0.046
  Cholesterol (mg/dL) 161.01 ± 39.01 165.12 ± 55.03 177.42 ± 60.72   > 0.05
  Triglyceride (mg/dL) 135.66 ± 42.29 145.61 ± 61.45 146.78 ± 64.08   > 0.05
  HDL(mg/dL) 38.29 ± 8.84 38.48 ± 56.32 37.17 ± 6.75   > 0.05
  LDL(mg/dL) 88.99 ± 5.38 (SEM) 94.73 ± 6.63 (SEM) 107.77 ± 7.89 (SEM)   > 0.05
  TNFα (pg/mL) 2521 ± 353.9 (SEM) 3403.08 ± 313.25 (SEM) 3760.35 ± 336.551 (SEM)        0.008
  IL-18 (ng/L) 37.16 ± 19.35 43.00 ± 13.192 46.311 ± 13.071        0.001
Table 4  Stratification of study subjects according to genotype distribution
1AA vs CC; 2AC vs CC. HDL: High density lipoprotein; LDL: Low density lipoprotein; TNFα: Tumor necrosis factor alpha; IL-18: Interleukin-18. 
0              10              20             30              40              50

















Figure 2  Correlation of interleukin-18 levels with body fat percentage. 
IL-18: Interleukin-18.
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ultra sonographic analysis. Nevertheless our results 
clearly show that IL-18 can be used a marker for obesity 
and supports the hypothesis that IL-18 may be involved 
in pathway of MetS and form a link between metabolic 
risk factors, diabetes, and cardiovascular diseases 
specially in south Asian population. 
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